Topics

Biological Principles and Applications of Chrono-immunotherapy

Cancer Immunotherapy Intercellular Communication & Diseases Cellular Stress Sleep Deprivation

Chrono-immunotherapy aligns immune treatment with circadian biology. Central and peripheral clocks generate daily rhythms in leukocyte trafficking, cytokines, antigen presentation, metabolism, hormone exposure, and tissue repair. Tumors can disrupt these rhythms yet remain influenced by time-dependent host immunity. Retrospective studies have associated the clock time of immune checkpoint inhibitor infusion with outcome, motivating prospective chronotherapy. These observations are hypothesis-generating rather than proof that one universal morning or afternoon schedule improves survival. Treatment time correlates with clinic workflow, patient behavior, disease severity, and geography, and immune rhythms differ among individuals. The field’s significance lies in testing timing as a low-cost, biologically informed variable Animal and human studies have long shown daily immune variation, but oncology now asks whether those rhythms are large and stable enough to guide treatment[1][2][3].

The molecular clock uses transcriptional feedback involving CLOCK, BMAL1, PER, and CRY proteins, while light, sleep, feeding, glucocorticoids, and autonomic signals synchronize tissues. Lymphocyte circulation between blood, lymphoid organs, and tissues follows rhythmic adhesion and chemokine cues. Dendritic-cell activity, innate sensing, cytokine production, and T-cell metabolism also vary by phase. Checkpoint blockade has a long pharmacologic half-life, but the first hours of receptor occupancy may coincide with different immune-cell distributions or activation states. A measured infusion time is only a proxy unless the patient’s internal phase is known Tumor clocks and host clocks may be misaligned, and advanced disease can flatten rhythmic signals, making healthy-volunteer patterns an unreliable dosing template[1][2].

Applications include scheduling PD-1 or PD-L1 antibodies, vaccines, cytokines, cellular infusions, and combination therapy at a biologically favorable phase. Circadian timing may also reduce toxicity if healthy-organ susceptibility and antitumor activity peak at different times. Practical implementation must consider repeated doses, shift work, travel, sleep disruption, steroid premedication, and hospital capacity. For long-lived antibodies, timing may matter less than for short-lived cytokines or vaccines, and a single clock time may not suit all chronotypes. Timing should not delay urgent treatment or reduce adherence without prospective evidence Cell therapies add another timing layer because collection, manufacturing, lymphodepletion, and infusion can each interact with endogenous immune and hormonal cycles[1][3].

Future trials should randomize timing while holding regimen, center, and supportive care constant. Wearables, sleep logs, melatonin or cortisol phase markers, and serial immune sampling can connect clock time to biological time and mechanism. Outcomes should include response, progression, survival, toxicity, and quality of life. Analyses must account for daylight-saving changes and local time. Chrono-immunotherapy could improve therapeutic index without inventing a new drug, but translation requires prospective validation and individualized phase assessment. The goal is not to declare a universally optimal hour; it is to identify reproducible relationships between circadian state, drug action, and antitumor immunity Pragmatic implementation should predefine an acceptable time window rather than an exact minute so that biological testing remains compatible with safe clinical operations. The most credible early application may be a well-tolerated scheduling adjustment within an existing regimen, followed by phase-guided personalization only after a reproducible clinical signal appears. Negative timing trials should also be reported transparently[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Peptides
  • Screening Libraries
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-14648 Dexamethasone
Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist, apoptosis inducer, and common disease inducer in experimental animals, constructing models of muscle atrophy, hypertension, and depression. Dexamethasone can inhibit the production of inflammatory miRNA-155 exosomes in macrophages and significantly reduce the expression of inflammatory factors in neutrophils and monocytes. Dexamethasone also has potential for use in COVID-19 research.
Exosomes   Glucocorticoid Receptor   SARS-CoV   Autophagy   Complement System   Mitophagy   Bacterial   Antibiotic   ADC Payloads  
Metabolic or Endocrine Disease   Prostate Cancer   Pancreatic Cancer   Viral Infection   Bacterial Infection   Fungal Infection   Pain   Autoimmune Disease   Digestive System Inflammation   Cardiovascular Disease   Non-Small Cell Lung Cancer   Lung Squamous Cell Carcinoma   Metastatic Breast Cancer   SARS-CoV-2 Infection   Lung Fibrosis  
402
HY-N0583 Hydrocortisone
Hydrocortisone (Cortisol) is a steroid hormone or glucocorticoid secreted by the adrenal cortex.
Environmental Pollutants   Glucocorticoid Receptor   Endogenous Metabolite  
Breast Cancer   Prostate Cancer   Pancreatic Cancer   Pain   Immunosuppression  
92
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L184 Anti-Gastric Cancer Compound Library
Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer. MCE designs a unique collection of 1,203 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

Disease Focused Libraries

83
HY-L227 Amino Acid Metabolite Compound Library
Amino acids are the fundamental components that sustain life activities, playing roles in ATP generation, promoting nucleotide synthesis, and maintaining cellular redox balance. Moreover, dysregulation of amino acid consumption is a significant potential regulatory mechanism leading to impaired anti-tumor immunity in immune cells. The normal functioning of immune cells relies on amino acid metabolic pathways to obtain energy and materials, and upon activation, they reprogram their metabolism to support growth, proliferation, and effector functions. Additionally, metabolic disorders of specific amino acids (such as branched-chain amino acids, glutamine, and arginine) can exacerbate mitochondrial dysfunction and oxidative stress, thereby promoting myocardial fibrosis and cardiac cell damage. Therefore, conducting research related to amino acid metabolism holds promise for discovering potential drugs for diseases related to cancer, immunity, and metabolism. MCE can provide 195 kinds of metabolites of amino acid metabolic pathways, which can be used for drug screening in various diseases such as cancer, immune disorders, metabolic diseases, mitochondrial-targeted diseases

Metabolism Focused Libraries

83
HY-L253 Fungal-Sourced Compound Library
For thousands of years, natural products have always been an important source for drug discovery. Fungi, due to their unique and diverse secondary metabolic capabilities, have become a valuable resource for natural active molecules. Since the discovery of penicillin, natural products derived from fungi have demonstrated significant application value in areas such as anti-infection, anti-tumor, immune regulation, and metabolic disease research. A large number of clinical drugs, such as antibiotics, immunosuppressants, and lipid-lowering drugs, are derived from fungal metabolites or their structurally optimized derivatives. MCE fungal-derived compound library contains 91 structurally diverse and bioactive fungal natural products and their derivatives. It can be widely applied in various research fields such as antibacterial, anti-tumor, anti-inflammatory, immune regulation, epigenetics, and cell signaling pathways, providing high-quality tools for natural product drug development and high-throughput screening.

Natural Product Screening Libraries

83
HY-L948 PD-1/PD-L1 Lead-like Library
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy. A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity. Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.

Focused and target libraries

83
HY-13683 Mifepristone
Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC50s of 0.2 nM and 2.6 nM in in vitro assay.
Endogenous Metabolite   Progesterone Receptor   Glucocorticoid Receptor   NO Synthase   Autophagy  
Metabolic or Endocrine Disease   Breast Cancer   Prostate Cancer   Viral Infection   Depression   Pain  
80
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-B1618 Corticosterone
Corticosterone (17-Deoxycortisol) is an orally active and adrenal cortex-produced glucocorticoid, which plays an important role in regulating neuronal functions of the limbic system (including hippocampus, prefrontal cortex, and amygdala). Corticosterone increases the Rab-mediated AMPAR membrane traffic via SGK-induced phosphorylation of GDI. Corticosterone also interferes with the maturation of dendritic cells and shows a good immunosuppressive effect.
Glucocorticoid Receptor   Endogenous Metabolite   iGluR  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Pain   SARS-CoV-2 Infection   Osteoarthritis  
71
HY-B2227 Lactic acid
Lactic acid (DL-Lactic acid) is a hydroxycarboxylic acid receptor 1 (HCAR1) activator and an epigenetic modulator inducing lysine residues lactylation. Lactic acid is a glycolysis end-product, bridging the gap between glycolysis and oxidative phosphorylation. Lactic acid is an oncometabolite and has immune protective role of lactate in anti-tumor immunity. Lactic acid also has antimicrobial activity, which can be used as a food preservative.
Environmental Pollutants   Hydroxycarboxylic Acid Receptor (HCAR)   Bacterial   Endogenous Metabolite  
Cancer   Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
67
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-B0469 Medroxyprogesterone acetate
Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with progesterone, androgen and glucocorticoid receptors.
Progesterone Receptor   Androgen Receptor   Glucocorticoid Receptor  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Pain   Cardiovascular Disease  
35
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-B0214 Prednisone
Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus.
Glucocorticoid Receptor   Apoptosis  
Metabolic or Endocrine Disease   Digestive System Disease   Prostate Cancer   Viral Infection   Pain   Digestive System Inflammation   Cardiovascular Disease   Lung Fibrosis  
22
HY-B0260 Methylprednisolone
Methylprednisolone (U 7532) is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels.
Glucocorticoid Receptor   Autophagy   SARS-CoV   Bacterial  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Breast Cancer   Prostate Cancer   Pancreatic Cancer   Viral Infection   Coronavirus Infection   Bacterial Infection   Depression   Pain   Cardiovascular Disease   Non-Small Cell Lung Cancer  
21
HY-B2227D Calcium 2-hydroxypropanoate pentahydrate
Calcium 2-hydroxypropanoate (pentahydrate) is a hydroxycarboxylic acid receptor 1 (HCAR1) activator and an epigenetic modulator inducing lysine residues lactylation. Calcium 2-hydroxypropanoate (pentahydrate) is a glycolysis end-product, bridging the gap between glycolysis and oxidative phosphorylation. Calcium 2-hydroxypropanoate (pentahydrate) is an oncometabolite and has immune protective role of lactate in anti-tumor immunity.
Environmental Pollutants   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
20
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-B1829A Dexamethasone phosphate disodium
Dexamethasone phosphate (Dexamethasone 21-phosphate) disodium is a prodrug form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone phosphate disodium is produced by introducing a phosphate ester group at the 21-position of the Dexamethasone molecule, forming a salt with sodium ions, thereby significantly improving water solubility. Dexamethasone phosphate disodium inhibits LPS (HY-D1056)-induced degradation of IRAK-1 and IRAK-4, and blocks LPS-induced activation of TRAF6, p-TAK1 and p-JNK. Dexamethasone phosphate disodium inhibits the secretion of RANTES, TGF-β1 and NO, promotes the production of MIP-1α and IL-10, and blocks microglial migration. Dexamethasone phosphate disodium is almost completely converted to Dexamethasone in rat blood, and supports transdermal delivery via iontophoresis. Dexamethasone phosphate disodium can be used in research related to steroid-dependent ulcerative colitis, chemotherapy-induced vomiting, allergic asthma and acute colitis (inflammatory bowel disease).
Glucocorticoid Receptor   TGF-β Receptor   Interleukin Related  
Neurological, Eye or Ear Disease   Ulcerative Colitis  
13
HY-17463 Prednisolone
Prednisolone is a potent, orally active corticosteroid and a glucocorticoid. Prednisolone possesses about four times the anti-inflammatory activity of hydrocortisone while causing less salt and water retention. Prednisolone can be used for ocular, anti-inflammatory research.
Glucocorticoid Receptor   Endogenous Metabolite  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Prostate Cancer   Viral Infection   Pain   Lung Fibrosis  
12
HY-N6653 Lentinan
Lentinan is an orally active biocompatible multifunctional polysaccharide with biological activities such as anti-inflammatory, antioxidant, immune regulation, anti-tumor, hypoglycemic, and lipid-lowering.
JAK   Keap1-Nrf2   Apoptosis  
Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
9
HY-P99032 Monalizumab
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

Species: Human

Checkpoint Kinase (Chk)   IFNAR  
Breast Cancer   Non-Small Cell Lung Cancer  
7
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-13580 Budesonide
Budesonide, an inhaled glucocortical steroid, is an orally active glucocorticoid receptor agonist. Budesonide decreases the size of lung tumors, reverses DNA hypomethylation and modulates mRNA expression of genes. Budesonide is an anti-inflammatory agent used for asthma.
Glucocorticoid Receptor   ADC Payloads  
Cancer   Inflammation or Immune System Disease   Viral Infection   Pain  
7
HY-N0587 Demethylzeylasteral
Demethylzeylasteral is an orally active triterpenoid compound isolated from Tripterygium wilfordii, which has functions such as anti-inflammatory, anti-tumor, anti fertility, estrogen metabolism regulation, immune suppression, and immune system regulation .
Apoptosis   TGF-beta/Smad   Estrogen Receptor/ERR   NF-κB   FAK  
Colorectal Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Triple-Negative Breast Cancer   Obesity   Lung Fibrosis  
6
HY-N0379 D-Mannose
D-Mannose is a C-2 superpolymer of glucose that occurs naturally in many plants and fruits. D-Mannose has anti-inflammatory and antitumor activity. D-Mannose plays an important role in immune regulation.
Environmental Pollutants   Endogenous Metabolite  
Cancer   SARS-CoV-2 Infection  
5
HY-112173 Prolylleucine
Prolylleucine (Z-Pro-D-Leu) is a dipeptide containing branched-chain amino acids. Prolylleucine (Z-Pro-D-Leu) can affect the circadian rhythms and behaviour of animals.
Others  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
4
HY-115672 KS15
KS15 is an inhibitor of the interactions between cryptochromes (CRYs: CRY1 and CRY2) and the CLOCK:BMAL1 heterodimer. KS15 impairs the feedback actions of CRYs on E-box-dependent transcription (EC50=4.9 μM) by CLOCK:BMAL1 heterodimer, an indispensable transcriptional regulator of the mammalian circadian clock. Anti-proliferative activity.
Cryptochrome  
Breast Cancer  
4
HY-P1812A AUNP-12 TFA
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
PD-1/PD-L1  
Cancer  
3
HY-P1812 AUNP-12
AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Ovarian Cancer  
3
HY-119506 KL044
KL044, a stabilizer of the clock protein cryptochrome (CRY) , is a potent chemical probe with a pEC50 value of 7.32, leading to the extension of the circadian period and repression of Per2 activity.
Cryptochrome  
Metabolic or Endocrine Disease  
2
HY-134194 KL201
KL201 a circadian clock modulator, is a isoform-selective cryptochrome 1 (CRY1) stabilizer. KL201 has no stabilizing effect on CRY2. KL201 lengthens the period of circadian rhythms in cells and tissues.
Cryptochrome  
Metabolic or Endocrine Disease  
2
HY-108468 KL001
KL001 is a first-in-class cryptochrome (CRY, a flavoproteins that are sensitive to blue light, and is involved in the circadian rhythms of plants and animals) stabilizer which specifically interacts with CRY1 and CRY2. KL001 prevents ubiquitin-dependent degradation of CRY, resulting in lengthening of the circadian period. KL001 has the potential to control fasting hormone-induced gluconeogenesis.
Cryptochrome  
Metabolic or Endocrine Disease  
2
HY-B1204S1 Histamine-d4
Histamine-d4 (Ergamine-d4) is deuterium labeled Histamine (HY-B1204). Histamine is the agonist for histamine receptor and a vasodilator. Histamine is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma.
Isotope-Labeled Compounds   Akt   Endogenous Metabolite   p38 MAPK   Apoptosis   Histamine Receptor   Reactive Oxygen Species (ROS)  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
1
HY-113440 5-Methoxytryptophol
5-Methoxytryptophol is a 5-methoxyindole alcohol structurally homologous to Melatonin (HY-B0075). It is secreted by the mammalian pineal gland and exhibits an inverse circadian rhythm. 5-Methoxytryptophol regulates bone metabolism by activating the ERK1/2 pathway. It reduces the levels of pro-inflammatory cytokines TNF-α and IL-1β, as well as proteolytic enzymes MMP-1 and MMP-2, in serum and dental pulp tissues, thereby ameliorating acute pulpitis. 5-Methoxytryptophol induces rapid sleep in mice, while high doses cause respiratory depression and death. 5-Methoxytryptophol. 5-Methoxytryptophol can be used in studies related to acute pulpitis, hypnosis, and bone metabolism.
Melatonin Receptor   ERK   TNF Receptor   Interleukin Related   MMP   Endogenous Metabolite  
Digestive System Disease   Sleep-Wake Disorder   Periodontal Disease   Osteoporosis  
1
HY-P99812 Ragifilimab
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab binds to and activates GITR on T cells, which stimulates the immune system to enhance its anti-tumor activity. Ragifilimab can be used for advanced or metastatic solid tumors research.

Species: Human

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
1
HY-N0379R D-Mannose (Standard)
D-Mannose (Standard) is the analytical standard of D-Mannose. This product is intended for research and analytical applications. D-Mannose is a C-2 superpolymer of glucose that occurs naturally in many plants and fruits. D-Mannose has anti-inflammatory and antitumor activity. D-Mannose plays an important role in immune regulation.
Reference Standards   Endogenous Metabolite  
1
HY-P2543 Neuropeptide Y (3-36) (human, rat)
Neuropeptide Y (3-36) (human, rat) is a neuropeptide Y fragment derived from humans or rats. Neuropeptide Y is an extremely abundant neurotransmitter in central and peripheral neurons, and it participates in the regulation of psychomotor activity, circadian rhythm, feeding behavior and cardiovascular function. Neuropeptide Y (3-36) (human, rat) can serve as a substrate to be sequentially degraded from its N-terminus by AfuS28, and it requires binding to AfuS28 and SedB to be decomposed into amino acids, dipeptides and tripeptides[1].
Neuropeptide Y Receptor  
Neurological, Eye or Ear Disease   Cardiovascular Disease  
1
HY-148764 M47
M47 is a molecular glue that selectively destabilizes Cryptochrome 1 (CRY1) and increases degradation of the CRY1 in the nucleus. M47 enhances apoptosis in Ras-transformed P53-deficient mouse skin fibroblast lines and enhances life span in p53 knockout mice. M47 can be used in research of cancer.
Molecular Glues   Cryptochrome   Apoptosis  
Cancer   Digestive System Disease   Digestive System Inflammation  
1
HY-P99144A Anti-Mouse PD-1 Antibody (S-5001)
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting PD-1, blocking the PD-1/PD-L1 immune checkpoint axis through competitive binding to PD-1. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy.

Species: Mouse

PD-1/PD-L1  
Cancer Immunology   Immunotherapy for Melanoma   Squamous Cell Carcinoma  
1
HY-148765 CLK8
CLK8 is a potent and specific CLOCK inhibitor that can disrupt the interaction between CLOCK and BMAL1 and interfere with nuclear translocation of CLOCK. CLK8 can be used for the research of disorders associated with dampened circadian rhythms.
Cryptochrome  
Cancer   Metabolic or Endocrine Disease  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P990031 Dargistotug
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function.

Species: Human

Transmembrane Glycoprotein  
Cancer   Inflammation or Immune System Disease  
/
HY-P11105 Short neuropeptide F
Short neuropeptide F is an insect neurohormone involved in regulating insect locomotor activity and circadian rhythm.
Others  
Neurological, Eye or Ear Disease  
/
HY-184895 CM002
CM002 is a circadian clock activator. CM002 inhibits the lineage commitment and terminal differentiation of preadipocytes by activating the circadian clock, thereby blocking the adipogenesis process driven by Wnt signaling-mediated transcriptional induction. CM002 attenuates lipid storage in a clock-dependent manner via inhibition of the lipogenic program in mature adipocytes. CM002 enhances circadian clock output across various adipose depots in both lean and obese mice through BMAL1/CLOCK-dependent metabolic reprogramming, inhibits adipocyte development and hypertrophy, and improves insulin sensitivity. CM002 can be used in research on obesity and type 2 diabetes.
Cryptochrome   REV-ERB   Nuclear Hormone Receptor 4A/NR4A   FABP   PARP   Fatty Acid Synthase (FASN)   Wnt   β-catenin   Hormone-Sensitive Lipase (HSL)   PGC-1α   ROR   GLUT  
Type 2 Diabetes   Obesity  
/
HY-B1812S3 Veratrole-d6
Veratrole-d6 is the deuterium labeled Veratrole. Veratrole (1,2-Dimethoxybenzene) is a key compound that widely exists in plants and attracts pollinators. The release of Veratrole has a circadian rhythm and plays an important role in plant reproduction, species differentiation, and interactions with pollinators. In addition, Veratrole can be demethylated by cytochrome P-450 in Streptomyces setonii.
Isotope-Labeled Compounds   Cytochrome P450  
/
HY-125911R Gossypin (Standard)
Gossypin (Standard) is the analytical standard of Gossypin. This product is intended for research and analytical applications. Gossypin is an orally active flavone isolated from Hibiscus vitifolius. Gossypin has antioxidant, antiinflammatory, anticancer, anticataract, antidiabetic, and hepatoprotective activities. Gossypin inhibits NF-κB and NF-κB-regulated gene expression. Gossypin inhibits AURKA and RSK2. Gossypin inhibits invasion and induces apoptosis. Gossypin can be used for gastric cancer study.
Reference Standards   NF-κB   Aurora Kinase   Ribosomal S6 Kinase (RSK)   Apoptosis   Bcl-2 Family   Caspase   Cryptochrome  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P2674 KDEL
KDEL is a tetrapeptide serving as an endoplasmic reticulum (ER) retrieval/retention signal. KDEL can target and deliver exogenous antigen peptides to the ER, significantly enhance and prolong MHC class I molecule presentation, and effectively boost anti-tumor immune responses.
MHC  
Cancer   Inflammation or Immune System Disease  
/
HY-B1812R Veratrole (Standard)
Veratrole (Standard) is the analytical standard of Veratrole. This product is intended for research and analytical applications. Veratrole (1,2-Dimethoxybenzene) is a key compound that widely exists in plants and attracts pollinators. The release of Veratrole has a circadian rhythm and plays an important role in plant reproduction, species differentiation, and interactions with pollinators. In addition, Veratrole can be demethylated by cytochrome P-450 in Streptomyces setonii.
Reference Standards   Cytochrome P450  
/
HY-W769991 Lactate sodium-13C2
Lactic acid-13C2 (DL-Lactic acid-13C2) sodium is the 13C-labeled Lactic acid sodium . Lactic acid (DL-Lactic acid) sodium is a hydroxycarboxylic acid receptor 1 (HCAR1) activator and an epigenetic modulator inducing lysine residues lactylation. Lactic acid sodium is a glycolysis end-product, bridging the gap between glycolysis and oxidative phosphorylation. Lactic acid sodium is an oncometabolite and has immune protective role of lactate in anti-tumor immunity. Lactic acid sodium also has antimicrobial activity, which can be used as a food preservative.
Isotope-Labeled Compounds   Bacterial   Hydroxycarboxylic Acid Receptor (HCAR)   Endogenous Metabolite  
Cancer  
/
HY-B1812S2 Veratrole-d10
Veratrole-d10 is the deuterium labeled Veratrole. Veratrole (1,2-Dimethoxybenzene) is a key compound that widely exists in plants and attracts pollinators. The release of Veratrole has a circadian rhythm and plays an important role in plant reproduction, species differentiation, and interactions with pollinators. In addition, Veratrole can be demethylated by cytochrome P-450 in Streptomyces setonii.
Isotope-Labeled Compounds   Cytochrome P450  
/
HY-P10610 Peptide 234CM
Peptide 234CM is a peptide containing isoleucine at position 3, corresponding to the sequence of a point mutation in p53 codon 234. Peptide 234CM induces potent cytotoxic T cell (CTL) and antitumor immune responses against mutant p53.
MDM-2/p53  
Cancer  
/
HY-B1637S Ditiocarb-d10 sodium
Ditiocarb-d10 sodium (Sodium diethyldithiocarbamate-d10) is the deuterium labeled Ditiocarb sodium (HY-B1637). Ditiocarb sodium (Sodium diethyldithiocarbamate) is an orally active copper reagent. Ditiocarb sodium exhibits activities such as antioxidation, chelation, anti-tumor effects, immunomodulation, and anti-HIV properties. Ditiocarb sodium can be used in the research of tumors, inflammatory, and immune-related diseases.
Isotope-Labeled Compounds   HIV   Biochemical Assay Reagents  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-B1204S4 Histamine-15N3
Histamine-15N3 is the 15N3-labeled Histamine (HY-B1204). Histamine is the agonist for histamine receptor and a vasodilator. Histamine is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma.
Isotope-Labeled Compounds   Akt   Endogenous Metabolite   p38 MAPK   Apoptosis   Histamine Receptor   Reactive Oxygen Species (ROS)  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-134192 TH301
TH301 is a Phenylpyrazole derivative. TH301 selectively stabilize CRY2. TH301 dose-dependently prolongs circadian period.
Drug Derivative   Cryptochrome  
/
HY-P10652 hsBCL9CT-24
hsBCL9CT-24 is a Wnt/β-catenin (b-cat) pathway inhibitor with potent anti-tumor effect. hsBCL9CT-24 reactivates anti-cancer immune response suppressed by the oncogenic Wnt pathway and can be utilized for cancer research.
Wnt   β-catenin  
/
HY-P10715 Fmoc-KCRGDK
Fmoc-KCRGDK is a self-assembling peptide that can be used to prepare hydrogels and assist in drug delivery for immune checkpoint inhibitors. Fmoc-KCRGDK can be applied in cancer immunotherapy research.
Others  
Inflammation or Immune System Disease  
/
HY-B0180S1 Imiquimod-d9
Imiquimod-d9 is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
Isotope-Labeled Compounds   Toll-like Receptor (TLR)   Autophagy   SARS-CoV   HSV  
Infection   Inflammation or Immune System Disease  
/
HY-B0180S Imiquimod-d6
Imiquimod-d6 is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
Toll-like Receptor (TLR)   Autophagy   SARS-CoV   HSV  
Infection   Inflammation or Immune System Disease  
/
HY-P991309 ZM-008
ZM-008 is an anti-LLT1 monoclonal antibody. ZM-008 blocks the interaction between LLT1 and CD161 on the surface of NK cells and T cells. ZM-008 restores anti-tumor immune activity, shifts the tumor microenvironment to an immune-responsive state, and recovers NK cell-mediated cytotoxicity against tumor cells, thereby reversing immunosuppression in immune-resistant "cold" tumors. ZM-008 is applicable to the research of immune-resistant solid tumors.

Species: Human

C-type Lectin-like Receptors (CTLRs)  
Cancer  
/
HY-P991443 IPH5301
IPH5301 is a human IgG1 monoclonal antibody (mAb) targeting NT5E/CD73. IPH5301 has a functionally silent Fc domain, specifically inhibits soluble and membrane CD73 enzyme activity, and restores the proliferation of immune T cells. IPH5301 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

CD73  
Cancer  
/
HY-B1812S4 Veratrole-d2-1
Veratrole-d2-1 is the deuterium labeled Veratrole (HY-B1812). Veratrole (1,2-Dimethoxybenzene) is a key compound that widely exists in plants and attracts pollinators. The release of Veratrole has a circadian rhythm and plays an important role in plant reproduction, species differentiation, and interactions with pollinators. In addition, Veratrole can be demethylated by cytochrome P-450 in Streptomyces setonii.
Isotope-Labeled Compounds   Cytochrome P450  
/
HY-P991395 TQB2618
TQB2618 is a human IgG4 monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. TQB2618 activates immune cell function and induces significant anti-tumor activity when used in combination with anti-PD-1 agents.

Species: Human

Tim3  
Cancer  
/
HY-P991391 COM902
COM902 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. COM902 enhances anti-tumor immune responses. COM902 can be used in Multiple myeloma, Solid tumours and Colorectal cancer research. Recommended isotype control: IgG4-lambda.

Species: Human

Transmembrane Glycoprotein  
Cancer  
/
HY-W653896 Alternariol-d2
Alternariol-d2 is deuterium labeled Alternariol. Alternariol is an orally ingested mycotoxin produced by Alternaria, capable of inhibiting the activity of topoisomerase I and II (topoisomerase I, topoisomerase II). Alternariol has weak estrogenic (Estrogen Receptor/ERR) and androgen/antiandrogen (Androgen Receptor) effects. Alternariol can induce apoptosis, trigger cell cycle arrest, suppress innate immune responses, and exhibit anti-tumor activity. Alternariol has genotoxic, mutagenic, and endocrine-disrupting effects.
Isotope-Labeled Compounds   Topoisomerase   Apoptosis   Androgen Receptor   Estrogen Receptor/ERR  
Infection  
/
HY-B0180S2 Imiquimod-d7
Imiquimod-d7 (R 837-d7) is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
Isotope-Labeled Compounds   HSV   Autophagy   Toll-like Receptor (TLR)   SARS-CoV  
Infection   Inflammation or Immune System Disease  
/
HY-113440R 5-Methoxytryptophol (Standard)
5-Methoxytryptophol (Standard) is the analytical standard of 5-Methoxytryptophol. This product is intended for research and analytical applications. 5-Methoxytryptophol is a 5-methoxyindole alcohol structurally homologous to Melatonin (HY-B0075). It is secreted by the mammalian pineal gland and exhibits an inverse circadian rhythm. 5-Methoxytryptophol regulates bone metabolism by activating the ERK1/2 pathway. It reduces the levels of pro-inflammatory cytokines TNF-α and IL-1β, as well as proteolytic enzymes MMP-1 and MMP-2, in serum and dental pulp tissues, thereby ameliorating acute pulpitis. 5-Methoxytryptophol induces rapid sleep in mice, while high doses cause respiratory depression and death. 5-Methoxytryptophol. 5-Methoxytryptophol can be used in studies related to acute pulpitis, hypnosis, and bone metabolism.
Reference Standards   Melatonin Receptor   MMP   Endogenous Metabolite   ERK   Interleukin Related   TNF Receptor  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P9994 Pertuzumab zuvotolimod
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research.
Antibody-Drug Conjugates (ADCs)   EGFR   Toll-like Receptor (TLR)  
Cancer   Inflammation or Immune System Disease  
/
HY-N0587R Demethylzeylasteral (Standard)
Demethylzeylasteral (Standard) is the analytical standard of Demethylzeylasteral. This product is intended for research and analytical applications. Demethylzeylasteral is an orally active triterpenoid compound isolated from Tripterygium wilfordii, which has functions such as anti-inflammatory, anti-tumor, anti fertility, estrogen metabolism regulation, immune suppression, and immune system regulation .
Reference Standards   Apoptosis   TGF-beta/Smad   Estrogen Receptor/ERR   NF-κB   FAK  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-D1056B2 Lipopolysaccharides, from Proteus mirabilis
Lipopolysaccharides, from Proteus mirabilis are lipopolysaccharide endotoxins and TLR-4 activators derived from Proteus mirabilis, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from Proteus mirabilis exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Proteus mirabilis is a major pathogen causing urinary tract infections and may also contribute to rheumatoid arthritis. Lipopolysaccharides, from Proteus mirabilis also exhibit potential anti-tumor effects, demonstrating in vivo inhibitory activity against solid tumors such as meningosarcoma and Walker carcinosarcoma.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-B1812S Veratrole-d4
Veratrole-d4 is the deuterium labeled Veratrole. Veratrole (1,2-Dimethoxybenzene) is a key compound that widely exists in plants and attracts pollinators. The release of Veratrole has a circadian rhythm and plays an important role in plant reproduction, species differentiation, and interactions with pollinators. In addition, Veratrole can be demethylated by cytochrome P-450 in Streptomyces setonii.
Isotope-Labeled Compounds   Cytochrome P450  
/
HY-P10610A Peptide 234CM TFA
Peptide 234CM TFA is a peptide containing isoleucine at position 3, corresponding to the sequence of a point mutation in p53 codon 234. Peptide 234CM TFA induces potent cytotoxic T cell (CTL) and antitumor immune responses against mutant p53.
MDM-2/p53  
Cancer  
/
HY-B1812S1 Veratrole-d2
Veratrole-d2 is the deuterium labeled Veratrole. Veratrole (1,2-Dimethoxybenzene) is a key compound that widely exists in plants and attracts pollinators. The release of Veratrole has a circadian rhythm and plays an important role in plant reproduction, species differentiation, and interactions with pollinators. In addition, Veratrole can be demethylated by cytochrome P-450 in Streptomyces setonii.
Isotope-Labeled Compounds   Cytochrome P450  
/
HY-P990778 Xirestomig
Xirestomig (ATG-101) is a tetravalent "2+2″ PD-L1×4-1BB bispecific antibody. Xirestomig binds PD-L1 and 4-1BB concurrently, with a greater affinity for PD-L1, and potently activated 4-1BB+ T cells when cross-linked with PD-L1-positive cells. Xirestomig activates exhausted T cells upon PD-L1 binding. Xirestomig displays potent antitumor activity in numerous in vivo tumor models, including those resistant or refractory to immune checkpoint inhibitors (ICIs).

Species: Human

TNF Receptor   PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-N9517 QS 7
QS 7 (QS 7 Api) is a triterpene saponin found in the bark of Quillaja saponaria and immune adjuvant with immune response potentiator activity. QS 7 can be used as vaccine adjuvant for the research of antitumor and antiviral vaccine development.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P99895 Rulonilimab
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity.

Species: Human

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-N6579 Arvenin I
Arvenin I is a natural cucurbitacin glucoside that activates T cells within the cancer-competitive environment. Arvenin I covalently reacts with and hyperactivates MKK3, thereby reviving the mitochondrial fitness of exhausted T cells through the activation of the p38MAPK pathway. Arvenin I exhibits broad-spectrum antiproliferative against cancer cells. Arvenin I enhances antitumor effects both as a monotherapy and in combination with immune checkpoint inhibitors in mice. Arvenin I can be used for cancer research, such as colon cancer, breast cancer, lung cancer, and ovarian cancer.
p38 MAPK   Mitochondrial Metabolism  
Cancer  
/
HY-P990704 Rilvegostomig
Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer.

Species: Human

PD-1/PD-L1   Transmembrane Glycoprotein  
Non-Small Cell Lung Cancer   Endometrial Cancer  
/
HY-P990259 Anti-Mouse CD96 Antibody (3.3)
Anti-Mouse CD96 Antibody (3.3) is a rat-derived anti-mouse CD96 IgG1 λ type antibody inhibitor. Anti-Mouse CD96 Antibody (3.3) blocks binding of CD155 to CD96. Anti-Mouse CD96 Antibody (3.3) can enhance the antitumor efficacy of multiple immune-checkpoint inhibitors. Anti-Mouse CD96 Antibody (3.3) shows potent anti-tumor and anti-metastatic activity in various tumor models. Anti-Mouse CD96 Antibody (3.3) can be used for the researches of cancer and inflammation, such as mammary carcinoma.

Species: Mouse

Transmembrane Glycoprotein  
Cancer   Inflammation or Immune System Disease  
/
HY-P10420 RS17
RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape.
CD47   Interleukin Related  
Cancer  
/
HY-76632 4-Hydroxyisophthalic acid
4-Hydroxyisophthalic acid activates antioxidant enzymes (such as catalase CAT and superoxide dismutase SOD), scavenges free radicals, and exhibits antioxidant property. 4-Hydroxyisophthalic acid activates AChE and BChE, enhances neuronal function and improves Tau-induced neurobehavioral defects. 4-Hydroxyisophthalic acid improves the cognitive defects, and ameliorates circadian rhythm disorders of fruit flies.
Cholinesterase (ChE)   SOD  
Neurodegenerative Disease  
/
HY-B2227BS Lactic acid-d4 sodium (60% w/w in water)
Lactic acid-d4 (DL-Lactic acid-d4) sodium (60% in water) is the deuterium labeled Lactic acid sodium (60% in water) (HY-B2227B) . Lactic acid (DL-Lactic acid) sodium (60% w/w in water) is a hydroxycarboxylic acid receptor 1 (HCAR1) activator and an epigenetic modulator inducing lysine residues lactylation. Lactic acid sodium (60% w/w in water) is a glycolysis end-product, bridging the gap between glycolysis and oxidative phosphorylation. Lactic acid sodium (60% w/w in water) is an oncometabolite and has immune protective role of lactate in anti-tumor immunity. Lactic acid sodium (60% w/w in water) also has antimicrobial activity, which can be used as a food preservative.
Isotope-Labeled Compounds   Bacterial   Hydroxycarboxylic Acid Receptor (HCAR)   Endogenous Metabolite  
Cancer   Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P5244 Tripeptide-32
Tripeptide-32 is a bioactive peptide that targets the PER1 gene. Tripeptide-32 can regulate circadian rhythms and stimulate the synthesis of cellular repair proteins, with anti-aging activity.
Others  
Metabolic or Endocrine Disease  
/
HY-P99836 Cudarolimab
Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research.

Species: Human

Orexin Receptor (OX Receptor)  
Cancer   Inflammation or Immune System Disease  
/
HY-B1812 Veratrole
Veratrole (1,2-Dimethoxybenzene) is a key compound that widely exists in plants and attracts pollinators. The release of Veratrole has a circadian rhythm and plays an important role in plant reproduction, species differentiation, and interactions with pollinators. In addition, Veratrole can be demethylated by cytochrome P-450 in Streptomyces setonii.
Cytochrome P450  
/
HY-P11303 PADRE peptide
PADRE peptide is a pan-HLA-DR binding epitope and immunostimulant. PADRE peptide binds to the peptide-binding groove of MHC class II molecules for presentation to CD4+ T cells, thereby effectively stimulating specific immune responses. PADRE peptide not only enhances anti-tumor immune responses, inhibits tumor growth and prolongs survival; it also significantly increases the frequency of E7-specific CD8+ T cells and improves therapeutic efficacy against TC-1 tumors when used in combination with E7 peptide-based vaccines and poly (I:C). The intensity of the immune response induced by PADRE peptide is lower than that of the Ii-PADRE DNA vaccine, and it fails to enhance the immune effect of CRT-E7 DNA. PADRE peptide is widely applicable to research on related tumors such as melanoma, glioblastoma and cervical cancer.
CD74   MHC  
Cervical Cancer   Glioblastoma  
/
HY-B2227BS1 Lactic acid-d3 sodium (60% w/w in water)
Lactic acid-d3 (DL-Lactic acid-d3) sodium (60% in water) is the deuterium labeled Lactic acid sodium (60% in water) (HY-B2227B) . Lactic acid (DL-Lactic acid) sodium (60% w/w in water) is a hydroxycarboxylic acid receptor 1 (HCAR1) activator and an epigenetic modulator inducing lysine residues lactylation. Lactic acid sodium (60% w/w in water) is a glycolysis end-product, bridging the gap between glycolysis and oxidative phosphorylation. Lactic acid sodium (60% w/w in water) is an oncometabolite and has immune protective role of lactate in anti-tumor immunity. Lactic acid sodium (60% w/w in water) also has antimicrobial activity, which can be used as a food preservative.
Isotope-Labeled Compounds   Bacterial   Hydroxycarboxylic Acid Receptor (HCAR)   Endogenous Metabolite  
Cancer   Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-59208 4-Quinolinol
4-Quinolone (Kynurine) is a quinoline derivative. Kynurine pathway modulates tryptophan metabolism and involves in neuroprotective effect. Kynurine promotes tumor cell survival and motility by suppressing antitumor immune.
Endogenous Metabolite  
Cancer   Neurological, Eye or Ear Disease  
/
HY-125911 Gossypin
Gossypin is an orally active flavone isolated from Hibiscus vitifolius. Gossypin has antioxidant, antiinflammatory, anticancer, anticataract, antidiabetic, and hepatoprotective activities. Gossypin inhibits NF-κB and NF-κB-regulated gene expression. Gossypin inhibits AURKA and RSK2. Gossypin inhibits invasion and induces apoptosis. Gossypin can be used for gastric cancer study.
NF-κB   Aurora Kinase   Ribosomal S6 Kinase (RSK)   Apoptosis   Caspase   Bcl-2 Family   PARP   Cryptochrome  
Breast Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Obesity  
/
HY-P990961 Palverafusp alfa
Palverafusp alfa (IMM-2510; SYN-2510) is a PD-L1/VEGF-targeting IgG1κ type humanized antibody. Palverafusp alfa blocks PD-1/PD-L1 binding, relieves immune suppression, mediates PD-L1-directed antibody-dependent cellular cytotoxicity (ADCC). Palverafusp alfa blocks VEGF/VEGFR binding, inhibits angiogenic signaling, relieves VEGF-induced immune suppression. Palverafusp alfa reduces endothelial cell proliferation, enhances ADCC and antibody-dependent cellular phagocytosis (ADCP), inhibits tumor growth, reverses T cell immune suppression. Palverafusp alfa exhibits immune stimulatory, antiangiogenic, and anti-tumor activity in the tumor microenvironment. Palverafusp alfa can be used for the research of cancer, such as solid tumors, non-small cell lung cancer.

Species: Human

VEGFR   PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P99166 Vudalimab
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.

Species: Human

PD-1/PD-L1   CTLA-4  
Cancer   Inflammation or Immune System Disease  
/
HY-P990650 PY159
PY159 is a humanized antibody targeting TREM1/CD354. PY159 reprograms immunosuppressive intratumoral myeloid cells towards an inflammatory, anti-tumor phenotype, promotes anti-tumor immune responses, upregulates monocyte activation markers, and induces proinflammatory cytokines. PY159 can be used for the research of platinum-resistant ovarian cancer, advanced solid tumors, and advanced refractory solid tumors.

Species: Human

TREM receptor  
Breast Cancer   Ovarian Cancer   Lung Adenocarcinoma  
/
HY-P99057 Varlilumab
Varlilumab (CDX-1127) is an agonist anti-CD27 monoclonal antibody. Varlilumab can promote T cell expansion and activate the immune response. Varlilumab has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors.

Species: Human

TNF Receptor   Transmembrane Glycoprotein  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
/
HY-P99950 Evorpacept
Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia.
CD47  
Leukemia/Lymphoma/Myeloma   Luminal Breast Cancer  
/
HY-13718 Oglufanide
Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascular endothelial growth factor (VEGF). Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities.

Source: calf thymus

VEGFR   HCV   Endogenous Metabolite  
Infection   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-B2227R Lactic acid (Standard)
Lactic acid (Standard) (DL-Lactic acid (Standard)) is the analytical standard of Lactic acid (HY-B2227). This product is intended for research and analytical applications. Lactic acid (DL-Lactic acid) is a hydroxycarboxylic acid receptor 1 (HCAR1) activator and an epigenetic modulator inducing lysine residues lactylation. Lactic acid is a glycolysis end-product, bridging the gap between glycolysis and oxidative phosphorylation. Lactic acid is an oncometabolite and has immune protective role of lactate in anti-tumor immunity. Lactic acid also has antimicrobial activity, which can be used as a food preservative.
Reference Standards   Bacterial   Hydroxycarboxylic Acid Receptor (HCAR)   Endogenous Metabolite  
Cancer   Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P6292A KS-133 TFA
KS-133 TFA is a highly selective and potent antagonist of the vascular active enteropeptide receptor 2 (VIPR2) with IC50 values for Ca influx measurement and cAMP measurement of 24.8 nM and 500 nM, respectively. KS-133 TFA reverses the tumor-promoting M2 phenotype of tumor-associated macrophages to the anti-tumor M1 phenotype, alters the tumor immune microenvironment, and inhibits tumor growth. KS-133 TFA can be used for research on schizophrenia and cancer immune regulation.
PACAP Receptor  
Cancer   Neurological, Eye or Ear Disease   Immunomodulation  
/
HY-P9986 Tiragolumab
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma.

Species: Human

CD28  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-W020780 mPEG5000-Mal
mPEG5000-Mal (mPEG5000-Maleimide) is a PEG-derived selective covalent binding agent for sulfhydryl groups (RSGs), which can form irreversible thioether bonds with sulfhydryl groups under near-neutral conditions via the maleimide group. The mechanism of action of mPEG5000-Mal can be divided into two categories: firstly, as an enzyme modifier, it binds to target proteins through hydrophobic interactions, hydrogen bonds, and van der Waals forces, altering the protein's secondary structure; secondly, as a nanoparticle surface modifier, it covalently binds to sulfhydryl groups on the surface of red blood cells, changing the surface properties and morphology of the red blood cells, leading to their phagocytosis by macrophages of the reticuloendothelial system. mPEG5000-Mal can react with free cysteine in proteins, increasing the apparent molecular weight of the modified protein by 10-15 kDa for detection purposes. mPEG5000-Mal can enhance the thermal stability and catalytic activity of enzymes, and improve the macrophage targeting of nanoparticles, enabling targeted drug delivery. mPEG5000-Mal can be applied in enzyme engineering research in the food industry and in oncology, assisting radiotherapy by inhibiting tumor-associated macrophage infiltration and enhancing anti-tumor immune responses.
Biochemical Assay Reagents  
/

Keywords

chrono-immunotherapy | circadian rhythms | immune checkpoint inhibitors | treatment timing | chronotherapy | antitumor immunity